Can A Dedicated Multidisciplinary Tumor Board Improve Personalized Medicine for Patients in Interventional Oncology? A Large Retrospective Single-Center Experience

OBJECTIVE Interventional oncology (IO) offers minimal invasive oncological procedures to personalize therapeu- tic approaches. We aimed at assessing potential advantages of an IO multidisciplinary tumor board (INTER-BOARD) in terms of waiting time, procedural adverse events, and length of hospital stay. METHODS We retrospectively evaluated all patients managed at our institutional INTER-BOARD from January 2018 to June 2019. Outcome measurements such as number of patients managed in each semester, me- dian interval time between initial assessment and admission to the hospital, total number of procedures, procedures type, adverse events, and complication-related days of hospital stay were analyzed. RESULTS The INTER-BOARD discussed 438 patients (mean age 64 years; range 27-92) during the study period. Overall, 203 procedures were performed in patients >65 years and 49 in patients >80 years. The number of patients discussed progressively increased over time 82 (18.7%) during the first semester, 120 (27.4%) during the second semester, and 236 (54.1%) in the third semester. Patients with 33 different cancer types were discussed and 22 different procedure types were performed. Mean hospitalization time was 4 days (progressively decreasing over time from 5 to 3 days). Adverse events occurred in 4% of cases, with a progressively decreasing rate over time (16%, 5%, and 3% for 1st, 2nd, and 3rd semester, respectively). CONCLUSION In our experience, the dedicated INTER-BOARD allowed optimization of patient care through critical evaluation of all treatment options offered by different specialists. This approach reached optimal treat- ment results, with low adverse events, and reduced waiting, as well as hospitalization time.

PDF

___

1. Tagliaferri L, Vavassori A, Lancellotta V, De Sanctis V, Barbera F, Fusco V, et al. Can brachytherapy be properly considered in the clinical practice? Trilogy project: The vision of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) Interventional Radiotherapy study group. J Contemp Brachytherapy 2020;12(1):84–9.
2. Yanazume Y, Yanazume S, Iio K, Yonekura R, Ko- jima N, Uchida N, et al. Major causes of impractical brachytherapy in elderly patients with uterine cervical cancer. J Obstet Gynaecol Res 2014;40(6):1725–32.
3. Colloca G, Tagliaferri L, Capua BD, Gambacorta MA, Lanzotti V, Bellieni A, et al. Management of the elderly cancer patients complexity: the radiation oncology potential. Aging Dis 2020;11(3):649–57.
4. Kovacs G, Tagliaferri L, Lancellotta V, Kovacs A, Iezzi R, Gambarcorta MA, et al. Interventional oncology: should interventional radiotherapy (brachytherapy) be integrated into modern treatment procedures? Turk J Oncol 2019;34(Supp 1):16–22.
5. Kovács G, Tagliaferri L, Valentini V. Is an Interven- tional Oncology Center an advantage in the service of cancer patients or in the education? The Gemelli Hospital and INTERACTS experience. J Contemp Brachytherapy 2017;9(6):497–8.
6. Bretschneider T, Ricke J, Gebauer B, Streitparth F. Image-guided high-dose-rate brachytherapy of ma- lignancies in various inner organs - technique, indi- cations, and perspectives. J Contemp Brachytherapy 2016;8(3):251–61.
7. Crocetti L, Iezzi R, Goldberg SN, Bilbao JI, Sami A, Akhan O, et al. The ten commandments of liver abla- tion: expert discussion and report from Mediterranean Interventional Oncology (MIOLive) congress 2017. Eur Rev Med Pharmacol Sci 2018;22(12):3896–904.
8. Malagari K, Iezzi R, Goldberg SN, Bilbao JI, Sami A, Akhan O, et al. The ten commandments of chemoem- bolization: expert discussion and report from Mediter- ranean Interventional Oncology (MIOLive) congress 2017. Eur Rev Med Pharmacol Sci 2018;22(2):372–81.
9. Bilbao JL, Iezzi R, Goldberg SN, Sami A, Akhan O, Giuliante F, et al. The ten commandments of he- patic radioembolization: expert discussion and re- port from Mediterranean Interventional Oncology (MIOLive) congress 2017. Eur Rev Med Pharmacol Sci 2017;21(18):4014–21.
10. Wildes TM, O'Donovan A, Colloca GF, Cheung KL. Tumour boards in geriatric oncology. Age Ageing 2018;47(2):168–70.
11. Colloca G, Corsonello A, Marzetti E, Balducci L, Landi F, Extermann M, et al. Treating cancer in older and old- est old patients. Curr Pharm Des 2015;21(13):1699– 705.
12. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen- Heijnen ML, Extermann M, et al. International Soci- ety of Geriatric Oncology consensus on geriatric as- sessment in older patients with cancer. J Clin Oncol 2014;32(24):2595–603.
13. Freeman RK, Van Woerkom JM, Vyverberg A, Asci- oti AJ. The effect of a multidisciplinary thoracic ma- lignancy conference on the treatment of patients with lung cancer. Eur J Cardiothorac Surg 2010;38(1):1–5.
14. Davies AR, Deans DA, Penman I, Plevris JN, Fletcher J, Wall L, et al. The multidisciplinary team meet- ing improves staging accuracy and treatment selec- tion for gastro-esophageal cancer. Dis Esophagus 2006;19(6):496–503.
15. Brännström F, Bjerregaard JK, Winbladh A, Nilbert M, Revhaug A, Wagenius G, et al. Multidisciplinary team conferences promote treatment according to guide- lines in rectal cancer. Acta Oncol 2015;54(4):447–53.
16. Wille-Jørgensen P, Sparre P, Glenthøj A, Holck S, Nør- gaard Petersen L, Harling H, et al. Result of the imple- mentation of multidisciplinary teams in rectal cancer. Colorectal Dis 2013;15(4):410–3.
17. Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil BJ. Tumor boards and the quality of cancer care. J Natl Cancer Inst 2013;105(2):113–21.
18. Boxer MM, Vinod SK, Shafiq J, Duggan KJ. Do multidisciplinary team meetings make a differ- ence in the management of lung cancer? Cancer 2011;117(22):5112–20.
19. Palmer G, Martling A, Cedermark B, Holm T. Pre- operative tumor staging with multidisciplinary team assessment improves the outcome in locally advanced primary rectal cancer. Colorectal Dis 2011;13(12):1361–9.
20. Santoso JT, Schwertner B, Coleman RL, Hannigan EV. Tumor board in gynecologic oncology. Int J Gynecol Cancer 2004;14(2):206–9
21. Wheless SA, McKinney KA, Zanation AM. A prospec- tive study of the clinical impact of a multidisciplinary head and neck tumor board. Otolaryngol Head Neck Surg 2010;143(5):650–4.
22. Specchia ML, Frisicale EM, Carini E, Di Pilla A, Cappa D, Barbara A, et al. The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res 2020;20(1):73.
23. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Correction to: Metastatic non-s- mall cell lung cancer: ESMO Clinical Practice Guide- lines for diagnosis, treatment and follow-up. Ann On- col 2019;30(5):863–70.
24. Haussmann J, Matuschek C, Bölke E, Orth K, Ghad- jar P, Budach W. The role of local treatment in oligometastatic and oligoprogressive cancer. Dtsch Arztebl Int 2019;116(50):849–56.
25. Tagliaferri L, Manfrida S, Barbaro B, Colangione MM, Masiello V, Mattiucci GC, et al. MITHRA - multipara- metric MR/CT image adapted brachytherapy (MR/ CT-IABT) in anal canal cancer: a feasibility study. J Contemp Brachytherapy 2015;7(5):336–45.
26. Frakulli R, Galuppi A, Cammelli S, Macchia G, Cima S, Gambacorta MA, et al Brachytherapy in non melanoma skin cancer of eyelid: a systematic review. J Contemp Brachytherapy 2015;7(6):497–502.
27. Tagliaferri L, Bussu F, Fionda B, Catucci F, Rigante M, Gambacorta MA, et al. Perioperative HDR brachyther- apy for reirradiation in head and neck recurrences: single-institution experience and systematic review. Tumori 2017;103(6):516–24.
28. Tagliaferri L, Garganese G, D'Aviero A, Lancellotta V, Fragomeni SM, Fionda B, et al. Multidisciplinary personalized approach in the management of vulvar cancer - the Vul.Can Team experience. Int J Gynecol Cancer 2020;30(7):932–8.
29. Tagliaferri L, Bussu F, Rigante M, Gambacorta MA, Autorino R, Mattiucci GC, et al. Endoscopy-guided brachytherapy for sinonasal and nasopharyngeal re- currences. Brachytherapy 2015;14(3):419–25.
30. Couñago F, Luna J, Guerrero LL, Vaquero B, Guillén- Sacoto MC, González-Merino T, et al. Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions. World J Clin Oncol 2019;10(10):318–39.
31. Fionda B, Massaccesi M, Tagliaferri L, Dinapoli N, Iezzi R, Boldrini L. Abscopal effect and interventional oncology: state of art and future perspectives. Eur Rev Med Pharmacol Sci 2020;24(2):773–6.
32. Valentini V, Maurizi F, Tagliaferri L, Cellini F. Spi- der: managing clinical data of cancer patients treated through a multidisciplinary approach by a palm based system. JPH 2008;5:66–76.
33. Tagliaferri L, Budrukkar A, Lenkowicz J, Cambeiro M, Bussu F, Guinot JL, et al. ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with inter- ventional radiotherapy (brachytherapy). J Contemp Brachytherapy 2018;10(3):260–6.